Kymera Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
atopic dermatitis and BREADTH in eosinophilic asthma) with enrollment expected to finish for AD by end-2026 and top-line AD data targeted mid-2027, after phase I/IB showed strong STAT6 degradation, biomarker reductions and tolerability that compared favorably to published dupilumab data at four weeks. The IRF5 degrader KT-579 began phase I dosing following IND clearance, with a translational goal of ~90% IRF5 degradation, planned ex vivo biomarker readouts, first-in-human data expected in H2 2026 and a patient proof-of-concept study in lupus thereafter. Kymera reported approximately $1.6 billion in cash after raising nearly $1 billion in 2025, giving a runway into 2029 to complete KT-621 phase IIb and advance KT-579, while collaborations with Gilead and Sanofi offer substantial milestone upside (up to $750M and nearly $1B, respectively). Interested in Kymera Therapeutics, Inc.? Here are five stocks we like better. Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy [Yahoo! Finance]Yahoo! Finance
- A Look At Kymera Therapeutics (KYMR) Valuation After Fast Track News And Gilead Collaboration Progress [Yahoo! Finance]Yahoo! Finance
- FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)'s KT-621 for Eosinophilic Asthma [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026GlobeNewswire
- Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe AsthmaGlobeNewswire
KYMR
Earnings
- 2/26/26 - Miss
KYMR
Sec Filings
- 4/24/26 - Form 4
- 4/24/26 - Form 4
- 4/22/26 - Form 144
- KYMR's page on the SEC website